To optimize therapeutic benefit, a pediatric-specific risk-warning model should be developed, which includes:A metabolic interaction database (e.g., Total Glycosides of Paeonia Lactiflora increasing cetirizine concentration by 23%); Growth and development monitoring indicators (e.g., limiting Ma Huang-containing formulas to ≤2 weeks); A syndrome-biomarker association system (e.g., for lung and spleen Qi deficiency, using IL-13 baseline levels to guide YG dosage). The gene discussed is IL13; the disease is Down syndrome.